Drug Profile
Research programme: NF-kappa B/IKK2 inhibitors - Uriach
Latest Information Update: 17 Aug 2007
Price :
$50
*
At a glance
- Originator Uriach
- Class
- Mechanism of Action I-kappa B kinase inhibitors; NF-kappa B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Autoimmune disorders; Cancer; Inflammation; Type 2 diabetes mellitus
Most Recent Events
- 17 Aug 2007 No development reported - Preclinical for Autoimmune disorders in Spain (unspecified route)
- 17 Aug 2007 No development reported - Preclinical for Cancer in Spain (unspecified route)
- 17 Aug 2007 No development reported - Preclinical for Inflammation in Spain (unspecified route)